Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis
| Autor: | Maruška Marovt, Pij B Marko, Irena Mlinarič-Raščan, Tanja Gmeiner, Jasna Grželj, Alenka Šmid |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Drug Adult Medicine (General) medicine.medical_specialty media_common.quotation_subject Kaplan-Meier Estimate Article methotrexate Cohort Studies R5-920 drug survival Psoriasis Internal medicine medicine farmakogenetika Humans media_common pharmacogenetics Proportional hazards model business.industry Hazard ratio General Medicine psoriasis medicine.disease psoriaza Multidrug Resistance-Associated Protein 2 Discontinuation Treatment Outcome Pharmaceutical Preparations udc:616.517-085 Cohort metotreksat Methotrexate Female Multidrug Resistance-Associated Proteins business zdravljenje luskavice Pharmacogenetics medicine.drug |
| Zdroj: | Medicina Volume 57 Issue 10 Medicina, vol. 57, no. 10, 1050, 2021. Medicina, Vol 57, Iss 1050, p 1050 (2021) |
| ISSN: | 1648-9144 |
| DOI: | 10.3390/medicina57101050 |
| Popis: | Background and Objectives: Methotrexate is widely prescribed for the treatment of moderate-to-severe psoriasis. As drug survival encompasses efficacy, safety, and treatment satisfaction, such studies provide insights into successful drug treatments in the real-life scenario. The objective was to define methotrexate drug survival and reasons for discontinuation, along with factors associated with drug survival, in a cohort of adult patients with moderate-to-severe plaque psoriasis. Materials and Methods: Data on methotrexate treatment were extracted from our institutional registry. Drug survival was estimated by Kaplan–Meier analysis, and predictors of drug survival were analyzed by Cox proportional hazards regression. Results: We included 133 patients treated with methotrexate. Due to significant effects of the year of treatment initiation, drug survival analysis was performed for 117 patients who started methotrexate in 2010 or later. Median methotrexate drug survival was 11.0 months. Overall, 89% of patients discontinued treatment, with over half of these (51%) due to lack of efficacy. Significantly longer drug survival was seen for patients who discontinued treatment due to lack of efficacy versus drug safety (p = 0.049) when stratified by sex, this remained significant only for women (p = 0.002). The patient ABCC2 rs717620 genotype was significantly associated with drug survival in both univariate log-rank and multivariate Cox regression analyses, with variant T allele associated with longer drug survival (hazard ratio, 0.606 95% confidence interval, 0.380–0.967 p = 0.036). Conclusions: We have identified the novel association of patient ABCC2 rs717620 genotype with methotrexate drug survival. This pharmacogenetic marker might thus help in the management of psoriasis patients in daily practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|